{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:07:07Z","timestamp":1784772427885,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neonatal Fc receptor (FcRn) blockade may represent a mechanism similar to plasma exchange (PLEX) in reducing immunoglobulin levels and thus have a broad implication for apheresis practitioners. Although only efgartigimod received FDA approval for myasthenia gravis in December 2021, multiple trials are currently underway with different FcRn therapies in a varied group of IgG antibody\u2010mediated neurological and hematological disorders which are outlined in this review. In this review we discuss FcRn's mechanism of action, and its potential use in various neurological and non\u2010neurological diseases. In addition, we further compare the kinetics and adverse events of PLEX and FcRn blockade. We encourage apheresis practitioners to be familiar with this class of drugs in order to better understand how these two therapies can be used either standalone, or in combination with other therapies as both FcRn antagonism and PLEX improve clinical state by reducing IgG levels and pathogenic antibodies.<\/jats:p>","DOI":"10.1002\/jca.22055","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T08:39:22Z","timestamp":1684139962000},"page":"632-640","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Neonatal <scp>Fc<\/scp> receptor blockade as emerging therapy in diseases with plasma exchange indications"],"prefix":"10.1002","volume":"38","author":[{"given":"Muharrem","family":"Yunce","sequence":"first","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakul","family":"Katyal","sequence":"additional","affiliation":[{"name":"Department of Neurology Stanford University School of Medicine  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Fortes","family":"Monis","sequence":"additional","affiliation":[{"name":"Department of Pathology University of California Davis  Sacramento California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Muppidi","sequence":"additional","affiliation":[{"name":"Department of Neurology Stanford University School of Medicine  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.015"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010021\u201000471\u20100"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311\u2010021\u201001175\u20107"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00538"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00159\u20109"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108"},{"key":"e_1_2_14_11_1","volume-title":"UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis","year":"2022"},{"key":"e_1_2_14_12_1","volume-title":"Phase 3, Multicenter, Randomized, Double\u2010Blind, Placebo\u2010Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis","author":"Janssen Research & Development, LLC","year":"2022"},{"key":"e_1_2_14_13_1","volume-title":"A Phase 3, Multi\u2010Center, Randomized, Quadruple\u2010Blind, Placebo\u2010Controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (GMG)","author":"Immunovant Sciences GmbH","year":"2022"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102014\u2010309697"},{"key":"e_1_2_14_15_1","volume-title":"Open\u2010Label Extension of the ARGX\u2010113\u20101802 Trial to Investigate the Long\u2010Term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","author":"argenx","year":"2023"},{"issue":"3","key":"e_1_2_14_16_1","volume":"27","author":"Querol L","year":"2022","journal-title":"J Periph Nerv Syst"},{"key":"e_1_2_14_17_1","volume-title":"A Phase 2b, Multi\u2010Center, Randomized, Quadruple\u2010Blind, Placebo\u2010Controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","author":"Immunovant Sciences GmbH","year":"2022"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19\u20102\u2010169"},{"key":"e_1_2_14_19_1","volume-title":"A Randomized, Double\u2010Blind, Placebo\u2010Controlled, Multicenter, Phase 3, Pivotal Study with an Open\u2010Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants with Myelin Oligodendrocyte Glycoprotein (MOG) Antibody\u2010Associated Disease (MOG\u2010AD)","author":"UCB Biopharma SRL","year":"2022"},{"key":"e_1_2_14_20_1","volume-title":"A Phase 2\/3, Randomized, Double\u2010Blinded, Placebo\u2010Controlled, Parallel\u2010Group, 2\u2010Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18\u2009Years and Older with Active Idiopathic Inflammatory Myopathy","author":"argenx","year":"2022"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25680"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863095"},{"key":"e_1_2_14_23_1","volume-title":"A Multicenter, Open\u2010Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)","author":"Janssen Research & Development, LLC","year":"2022"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21705"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21257"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12629"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010018\u201023481\u20105"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1276"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2016.1214823"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20143"},{"issue":"1","key":"e_1_2_14_33_1","first-page":"8","article-title":"Complications of therapeutic plasma exchange in patients with neurological disorders","volume":"19","author":"Afzali M","year":"2020","journal-title":"Curr J Neurol"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744\u20109987.2009.00684.x"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002003"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.22055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T01:29:23Z","timestamp":1697074163000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.22055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/jca.22055"],"URL":"https:\/\/doi.org\/10.1002\/jca.22055","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"2022-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}